MA39927B1 - Inhibiteurs de glyt1 pour le traitement de troubles hématologiques - Google Patents
Inhibiteurs de glyt1 pour le traitement de troubles hématologiquesInfo
- Publication number
- MA39927B1 MA39927B1 MA39927A MA39927A MA39927B1 MA 39927 B1 MA39927 B1 MA 39927B1 MA 39927 A MA39927 A MA 39927A MA 39927 A MA39927 A MA 39927A MA 39927 B1 MA39927 B1 MA 39927B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- hematological disorders
- glyt1 inhibitors
- glyt1
- inhibitors
- Prior art date
Links
- 208000014951 hematologic disease Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000033981 Hereditary haemochromatosis Diseases 0.000 abstract 1
- 206010065973 Iron Overload Diseases 0.000 abstract 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention se rapporte à des composés, qui sont des inhibiteurs de glyt1, destinés à être utilisés dans le traitement de troubles hématologiques, en particulier destinés à être utilisés dans le traitement de la drépanocytose et de la thalassémie, ou dans le traitement de patients atteints de syndromes de surcharge en fer, tels que l'hémochromatose héréditaire.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166497 | 2014-04-30 | ||
| PCT/EP2015/059037 WO2015165842A1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 destinés à être utilisés dans le traitement de troubles hématologiques |
| EP15717916.9A EP3137073B1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39927A MA39927A (fr) | 2017-03-08 |
| MA39927B1 true MA39927B1 (fr) | 2018-09-28 |
Family
ID=50677958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39927A MA39927B1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9877963B2 (fr) |
| EP (1) | EP3137073B1 (fr) |
| JP (1) | JP6283766B2 (fr) |
| KR (1) | KR101869185B1 (fr) |
| CN (1) | CN106163520B (fr) |
| AR (1) | AR100209A1 (fr) |
| CY (1) | CY1120508T1 (fr) |
| ES (1) | ES2683184T3 (fr) |
| HR (1) | HRP20181205T1 (fr) |
| MA (1) | MA39927B1 (fr) |
| MY (1) | MY189930A (fr) |
| PH (1) | PH12016501784B1 (fr) |
| PT (1) | PT3137073T (fr) |
| RS (1) | RS57535B1 (fr) |
| SG (2) | SG10201909382UA (fr) |
| SI (1) | SI3137073T1 (fr) |
| TR (1) | TR201809598T4 (fr) |
| WO (1) | WO2015165842A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199156A1 (fr) * | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Utilisation d'antagonistes du transporteur de la glycine 1 comme analgésiques du systeme nerveux central |
| CU20200106A7 (es) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| CN116212025A (zh) * | 2020-01-09 | 2023-06-06 | 迪斯克医药公司 | 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| AU2022232452A1 (en) * | 2021-03-12 | 2023-10-26 | Disc Medicine, Inc. | Compositions and methods for treating anemia associated with a ribosomal disorder |
| CN117979967A (zh) * | 2021-05-14 | 2024-05-03 | 迪斯克医药公司 | 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| CN118043050A (zh) * | 2021-05-27 | 2024-05-14 | 迪斯克医药公司 | 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| AU2023280302A1 (en) * | 2022-05-31 | 2024-11-28 | Disc Medicine, Inc. | Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1656361T3 (da) * | 2003-08-11 | 2008-05-05 | Hoffmann La Roche | Piperazin med OR-substitueret phenylgruppe og anvendelse deraf som GLYT1-inhibitorer |
| BRPI0607311A2 (pt) * | 2005-02-07 | 2009-08-25 | Hoffmann La Roche | fenil metanonas substituìdas com heterociclila como inibidores do transportador de glicina 1 |
-
2015
- 2015-04-27 SG SG10201909382U patent/SG10201909382UA/en unknown
- 2015-04-27 PT PT157179169T patent/PT3137073T/pt unknown
- 2015-04-27 EP EP15717916.9A patent/EP3137073B1/fr active Active
- 2015-04-27 JP JP2017505724A patent/JP6283766B2/ja active Active
- 2015-04-27 MY MYPI2016001545A patent/MY189930A/en unknown
- 2015-04-27 SI SI201530334T patent/SI3137073T1/sl unknown
- 2015-04-27 SG SG11201608397UA patent/SG11201608397UA/en unknown
- 2015-04-27 WO PCT/EP2015/059037 patent/WO2015165842A1/fr active Application Filing
- 2015-04-27 TR TR2018/09598T patent/TR201809598T4/tr unknown
- 2015-04-27 KR KR1020167030222A patent/KR101869185B1/ko active IP Right Grant
- 2015-04-27 MA MA39927A patent/MA39927B1/fr unknown
- 2015-04-27 CN CN201580016721.4A patent/CN106163520B/zh active Active
- 2015-04-27 ES ES15717916.9T patent/ES2683184T3/es active Active
- 2015-04-27 RS RS20180897A patent/RS57535B1/sr unknown
- 2015-04-28 AR ARP150101268A patent/AR100209A1/es not_active Application Discontinuation
-
2016
- 2016-09-13 PH PH12016501784A patent/PH12016501784B1/en unknown
- 2016-10-26 US US15/334,722 patent/US9877963B2/en active Active
-
2018
- 2018-07-25 HR HRP20181205TT patent/HRP20181205T1/hr unknown
- 2018-08-06 CY CY20181100809T patent/CY1120508T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017511385A (ja) | 2017-04-20 |
| PH12016501784A1 (en) | 2016-11-07 |
| KR20160130517A (ko) | 2016-11-11 |
| PH12016501784B1 (en) | 2016-11-07 |
| US20170042888A1 (en) | 2017-02-16 |
| US9877963B2 (en) | 2018-01-30 |
| MA39927A (fr) | 2017-03-08 |
| EP3137073B1 (fr) | 2018-06-06 |
| CN106163520A (zh) | 2016-11-23 |
| AR100209A1 (es) | 2016-09-21 |
| JP6283766B2 (ja) | 2018-02-21 |
| CN106163520B (zh) | 2019-12-13 |
| CY1120508T1 (el) | 2019-07-10 |
| SG10201909382UA (en) | 2019-11-28 |
| SI3137073T1 (sl) | 2018-09-28 |
| KR101869185B1 (ko) | 2018-06-19 |
| PT3137073T (pt) | 2018-07-27 |
| HRP20181205T1 (hr) | 2018-09-21 |
| TR201809598T4 (tr) | 2018-07-23 |
| WO2015165842A1 (fr) | 2015-11-05 |
| MY189930A (en) | 2022-03-22 |
| EP3137073A1 (fr) | 2017-03-08 |
| SG11201608397UA (en) | 2016-11-29 |
| ES2683184T3 (es) | 2018-09-25 |
| RS57535B1 (sr) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39927B1 (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA41013A (fr) | Compositions comprenant des souches bactériennes | |
| MA53937A (fr) | Compositions comprenant des souches bactériennes | |
| MA38814A1 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
| MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA44322A (fr) | Compositions comprenant des souches bactériennes | |
| MA42471A (fr) | Compositions comprenant des souches bactériennes | |
| MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| EP3334484A4 (fr) | Compositions et méthodes qui favorisent l'hypoxie ou la réponse hypoxique pour le traitement et la prévention d'un dysfonctionnement mitochondrial et de troubles du stress oxydatif | |
| MA41185B1 (fr) | Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc | |
| MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| EP2571360A4 (fr) | Méthodes et formulations pour le traitement par l'oxytocine de troubles liés à l'utilisation de substances toxiques, de troubles psychiatriques et autres troubles | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA41977B1 (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
| MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| TN2016000040A1 (fr) | Inhibiteurs de porc2 et procedes pour leur utilisation | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| MA42776B1 (fr) | Composés utiles pour l'inhibition du ror-gamma-t | |
| FR2992862A1 (fr) | Utilisation d'un extrait de myrte en tant qu'agent anti-biofilm vis-a-vis de p. acnes |